CatalYm is strategically enhancing its leadership team to accelerate the late-stage trials of Visugromab, a pivotal therapy targeting GDF-15 in cancer and cachexia. These executive appointments signal the company’s commitment to advancing its innovative pipeline and optimizing operational efficiency as it prepares for significant growth.
MUNICH & SAN FRANCISCO–(BUSINESS WIRE)–CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief Financial Officer and Chief Business Officer; Sujata Rao, MD, as Chief Medical Officer; Heike Krupka, PhD, as Chief Development Officer and Andrea Goddard as Chief Technology Officer represent a significant addition to the company’s international dev
Source: Original Press Release
